Experts in Health Economics&Outcomes Research, Access, and Value Consulting
About HTE
Health Through Evidence (HTE) is a leading provider of HEOR and market access services for the pharmaceutical, biotech, and medical device industry. We provide evidence-based solutions to generate a greater understanding of the clinical and economic value of your products for payers, regulators, patients, and prescribers.
Our expertise spans HEOR, health technology assessments, market access and reimbursement strategy, real-world evidence generation, systematic literature reviews, medical writing, stakeholder engagement and value communication.
Health Economics
Market Access & Reimbursement Strategy
Evidence Review, Generation & Synthesis
Value Communication
Training
Expertise
Why Us?
HTE team is fully skilled and experienced in generating the evidence needed to optimize the market access and convey the merit of your products to key healthcare decision-makers. From HEOR and market research to HTA submissions and value communication materials, we bring together broad specialist expertise to meet your objectives.
We work closely with you to ensure the direction of research is fully aligned with your needs and promotes the conversion of scientific evidence into actionable insights. Our strong project management, validation, and quality control processes ensure we consistently provide you with the highest-quality deliverables on time and within budget.
HTE is dedicated to contributing to the translation of new knowledge into clinical practice, offering extensive experience in full breadth of therapeutic areas. HTE is built on a passion for science and research, renowned for high-quality deliverables, flexibility, integrity to scientific principles and best practice, and philosophy of true partnership.
Recent News
News
<
Archives
Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
Happy to share our latest publication about the potential health and economic impact of switching the current 13-valent Pneumococcal Conjugate Vaccine (PCV13) among the Greek paediatric Vaccination programme with higher-valent conjugate vaccines. Find out more at:...
